Observational Study With InnoLet® in Daily Clinical Practice
Completed
- Conditions
- Diabetes Mellitus, Type 1DiabetesDiabetes Mellitus, Type 2
- Interventions
- Registration Number
- NCT01492959
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This study is conducted in Asia. The aim of this study is to review the efficacy and safety of insulin treatment with InnoLet® in daily clinical practice.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1030
Inclusion Criteria
- Diabetes mellitus (Type 1 or type 2)
- Need insulin treatment
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Insulin human insulin human -
- Primary Outcome Measures
Name Time Method Change in HbA1c (glycosylated haemoglobin)
- Secondary Outcome Measures
Name Time Method Adverse events: Serious and non-serious
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie insulin human efficacy in Type 1 and Type 2 diabetes using InnoLet®?
How does InnoLet® compare to standard-of-care insulin delivery devices in Asian diabetes populations?
Are there specific biomarkers that predict optimal response to InnoLet® insulin therapy in clinical practice?
What adverse events are associated with InnoLet® insulin pens in daily management of diabetes mellitus?
What combination therapies or alternative insulin delivery systems are being developed by Novo Nordisk for diabetes treatment?
Trial Locations
- Locations (1)
Novo Nordisk Investigational Site
🇰🇷Seoul, Korea, Republic of
Novo Nordisk Investigational Site🇰🇷Seoul, Korea, Republic of